[Therapeutic efficacy and safety of off-label use of Bevacizumab for the treatment of neovascular diseases of the eye].
Clinical trial of off-label use of Bevacizumab for the treatment of neovascular diseases of the eye showed good therapeutic results. It has been demonstrated that this therapy is efficient and safe in the treatment of choroidal neovascularization due to age-related macular degeneration, pathologic myopia and other neovascular eye diseases in short term period. The potential risks to the patients are minimal, and the cost-effectiveness is so obvious that the treatment strategy using intravitreal bevacizumab is logical and understandable.